Royalty Pharma

If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Royalty Pharm

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization of

Royalty Pharma EVP Christopher Hite sells $5.85m in shares

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? | The Motley Fool

Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.

Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run

Royalty Pharma has delivered a strong share price run in recent years, which naturally puts fresh attention on what investors are paying for its earnings today. With the stock now around US$58.52, the key issue is how that outcome lines up with the underlying profit engine of its royalty portfolio. Over the last 3 years, Royalty Pharma has returned about 136.3%, which increases the stakes on whether its current earnings base can carry that kind of share price progress. The recent US$7.5...

Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns

Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program

Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.